New Zealand's PHARMAC consultation on exceptional circumstances for drug funding
The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on proposed changes to its Exceptional Circumstances policy. Currently the three exceptional circumstances schemes provide pharmaceutical funding consideration for patients in rare or unusual medical situations, where there are cost-savings to hospitals and for cancer patients in certain circumstances.
The first phase of PHARMAC’s review of Exceptional Circumstances, announced by Health Minister Tony Ryall in August 2010, involved seeking the views of interested parties on how the policy could be improved. PHARMAC received more than 70 responses from a broad range of stakeholders, which have informed the proposals described in the current consultation document.
New single scheme proposed
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze